Geneva Risk Score for Venous Thromboembolism (VTE) Prophylaxis
The Geneva Risk Score estimates a medical inpatient’s likelihood of hospital‑associated VTE to guide need for prophylaxis.
Indications for Use
Used for hospitalized medical inpatients to identify those at elevated VTE risk needing pharmacologic prophylaxis and to avoid prophylaxis in low‑risk patients (external validation across multiple cohorts) 1 [Level II evidence]. Provides moderate discrimination but improves appropriate prophylaxis rates in impact studies 2 [Level II evidence]. Best applied within a risk-adapted prophylaxis strategy when bleeding risk is acceptable.
Insights & Cautions
Start by recognizing limited accuracy: the simplified and original versions show poor discrimination (AUC <0.60) for predicting 90‑day VTE in medical inpatients 1 [Level II evidence]. Use cautiously—high sensitivity but low specificity leads to overclassification, and mobility/infection risk is frequently misjudged. Do not rely on it alone for prophylaxis decisions; integrate clinical judgment and bleeding‑risk assessment, as impact studies show improved prophylaxis rates but modest predictive value 2 [Level II evidence].